<DOC>
	<DOC>NCT01152619</DOC>
	<brief_summary>This multi-center, randomized, observer-blinded, placebo-controlled study will evaluate the safety and tolerability of subcutaneous doses of RO4989991 in patients with allergic rhinitis who are otherwise healthy. The anticipated time on study treatment is 2 weeks.</brief_summary>
	<brief_title>A Study of RO4989991 in Patients With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Adult patients, 1865 years of age, inclusively A history of allergic rhinitis diagnosed by a physician, but otherwise healthy A positive skin prick test to at least one standardized allergen at screening A body mass index (BMI) between 18 and 32 kg/m2, inclusively History or presence of any respiratory disease or condition other than allergic rhinitis Use of prescription medication or herbal remedies within 14 days of dosing the study drug Use of overthecounter (OTC) medications within 7 days of dosing the study drug Acute infection (including viral infections) 6 weeks (8 weeks for respiratory infections) preceding dosing or any ongoing chronic infection Positive test for human immunodeficiency virus (HIV) or hepatitis B or C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>